Supplementary Material

Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis

Plasma extracellular vesicles and ALS

Laura Pasetto¹, Stefano Callegaro², Deborah Ferrara³, Laura Brunelli¹, Giovanna Sestito¹, Roberta Pastorelli¹, Elisa Bianchi¹, Alessandro Corbelli¹, Fabio Fiordaliso¹, Marina Cretich⁴, Marcella Chiari⁴ Cristina Potrich⁵, Cristina Moglia⁶, Massimo Corbo⁷, Gianni Sorarù⁸, Christian Lunetta⁹, Andrea Calvo⁶, Adriano Chiò⁶, Gabriele Mora¹⁰, Maria Pennuto^{11,12}, Alessandro Quattrone³, Francesco Rinaldi², Vito D'Agostino³, Manuela Basso^{1,3*}, and Valentina Bonetto^{1*}

¹Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano (Italy)

² Department of Mathematics "Tullio Levi-Civita", University of Padova

³Department of Cellular, Computational and Integrative Biology – CIBIO, University of Trento, Trento, Italy

⁴Consiglio Nazionale delle Ricerche, Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC-CNR), Milano, Italy

⁵ Centre for Materials and Microsystems, Fondazione Bruno Kessler, Trento, Italy & Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Trento, Italy

⁶ Rita Levi Montalcini' Department of Neuroscience, Università degli Studi di Torino, Torino, Italy

⁷Department of Neurorehabilitation Sciences, Casa Cura Policlinico (CCP), Milano, Italy

⁸ Department of Neuroscience, University of Padova, 35122 Padova, Italy

⁹NEuroMuscular Omnicentre (NEMO), Serena Onlus Foundation, Milano

¹⁰Department of Neurorehabilitation, ICS Maugeri IRCCS, Milano, Italy

¹¹ Department of Biomedical Sciences (DBS), University of Padova, 35131 Padova, Italy.

¹² Veneto Institute of Molecular Medicine (VIMM), 35129 Padova, Italy.

*These are co-corresponding and co-last authors.

Supplementary Figure 1. NBI enriches for a higher number and a smaller average diameter plasma EVs than classical ultracentrifugation (UC). A) Immunoblotting for flotillin-1 in a pool of human plasma and relative Red Ponceau. '1°-2°-3°UC' stands for first, second, third ultracentrifugation. 'EVs' and 'Sur' are the pellet and supernatant after the UC. B) TEM of EVs purified with UC. Bar, 200 nm on the left; 100 nm and 200 nm in the insets on the right. C) TRPS analysis for the particle amount per ml (Particles/ml) with the NP200 nanopore of control plasma EVs (n=15) extracted with either NBI or UC. Student t-test; ****p<0.0001. D) TRPS analysis with the NP400 nanopore of control plasma EVs (n=15) for the particle amount per ml (Particles/ml) extracted with either NBI or UC. Student t-test; *p=0.037. E) TRPS analysis with the NP200 nanopore of control plasma EVs (n=15) for the mean diameter (nm) extracted with either NBI or UC. Student t-test; ****p<0.0001. F) TRPS analysis with the NP200 nanopore of control plasma EVs (n=15) for the mean diameter (nm) extracted with either NBI or UC. Student t-test; ****p<0.0001. G) Purity index for samples extracted with NBI and UC, calculated by the ratio between the number of particles and the total micrograms of proteins detected in the relative EV samples; Student t-test; **p=0.007. H) Size distribution of liposomes isolated with three independent NBI extractions (NBI1, NBI2, NBI3). I) Size distribution of liposomes isolated with three independent UC extractions (UC1, UC2, UC3). J) Venn diagram of the unique and shared EV identified proteins isolated by NBI and UC methods. Numbers in brackets refer to the number of proteins belonging to each class.

Supplementary Figure 2. Zeta potential and additional size parameters for EV plasma of ALS, HC, MD and SBMA. A) Box plot for the average zeta potential (z-potential) for ALS, HC, MD and SBMA. B) Box plot presenting the mode diameter (nm) of EVs purified from ALS, HC, MD and SBMA plasma. One-way ANOVA, p=0.019; Wilcoxon-Mann-Whitney *post hoc*, *p=0.027 between ALS and MD. **C)** Box plot showing the D10 (nm) of EVs purified from ALS, HC, MD and SBMA plasma. One-way ANOVA, p=0.016; Wilcoxon-Mann-Whitney *post hoc*, **p=0.005 between ALS and MD. **D)** Box plot showing the D50 (nm) of EVs purified from ALS, HC, MD and SBMA plasma. One-way ANOVA, p=0.002; Wilcoxon-Mann-Whitney *post hoc*, **p=0.020 between ALS and MD, *p=0.012 between ALS and SBMA. **E)** Box plot showing the D90 (nm) of EVs purified from ALS, HC, MD and SBMA plasma. One-way ANOVA, p=0.011; Wilcoxon-Mann-Whitney *post hoc*, *p=0.027 between ALS and MD. **F)** Normalized curves. **G)** Representative image of the compressed size distribution using RBF. The green points are selected center, the black line is the initial signal and the red line is the RBF- output signal. Supplementary Figure 3. Representative immunoblotting for HSP-90 (A), phosphorylated TDP-43 (B) and PPIA (C) and relative red Ponceau in human EV samples. IS means internal standard. F, familial; S, sporadic. The numbers appearing next to the different samples represent the actual number we assigned to each sample.

Supplementary Figure 4. Set up for the immunoblotting against TDP-43 and phosphorylated TDP-43 in human and mouse plasma EVs, representative experiments. A) Immunoblotting for anti-TDP-43 (C-terminus) in human samples. B) Immunoblotting for anti-TDP-43 (N-terminus) in human samples. C) Immunoblotting for anti-phosphorylated TDP-43 (pTDP-43) in human samples.
D) Red Ponceau relative to A, B and C. E) Immunoblotting for anti-TDP-43 (N-terminus) in mouse samples. Asterisks indicate post translationally modified and truncated forms of TDP-43 that together with the form at 45-50 kDa were considered for WB quantification. F) Red Ponceau relative to E.

Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure 4

